Scientific Publications by FDA Staff
J Pharm Sci 2014 May;103(5):1331-6
United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise.
Khan SR, Kona R, Faustino PJ, Gupta A, Taylor JS, Porter DA, Khan M
The Department of Defense (DoD)-United States Food and Drug Administration (FDA) shelf-life extension program (SLEP) was established in 1986 through an intra-agency agreement between the DoD and the FDA to extend the shelf life of product nearing expiry. During the early stages of development, special attention was paid to program operation, labeling requirements, and the cost benefits associated with this program. In addition to the substantial cost benefits, the program also provides the FDA's Center for Drug Evaluation and Research with significant scientific understanding and pharmaceutical resource. As a result of this unique resource, numerous regulatory research opportunities to improve public health present themselves from this distinctive scientific database, which includes examples of products shelf life, their long-term stability issues, and various physical and chemical tests to identify such failures. The database also serves as a scientific resource for mechanistic understanding and identification of test failures leading to the development of new formulations or more robust packaging. It has been recognized that SLEP is very important in maintaining both national security and public welfare by confirming that the stockpiled pharmaceutical products meet quality standards after the "expiration date" assigned by the sponsor. SLEP research is an example of regulatory science that is needed to best ensure product performance past the original shelf life. The objective of this article is to provide a brief history and background and most importantly the public health benefits of the SLEP. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
|Category: Journal Article|
|PubMed ID: #24623105||DOI: 10.1002/jps.23925|
|Includes FDA Authors from Scientific Area(s): Drugs Regulatory Affairs|
|Entry Created: 2014-03-14||Entry Last Modified: 2014-06-04|